Trial Profile
Cognitive performance (assessed by clinician and reported by patient) between vortioxetine, escitalopram and venlafaxine at standard doses in patients with major depressive disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary) ; Venlafaxine (Primary) ; Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 05 Oct 2021 Results presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
- 27 Nov 2017 New trial record